Failure to protect against myocardial ischemia-reperfusion injury with sevoflurane postconditioning in old rats in vivo

Acta Anaesthesiol Scand. 2013 Sep;57(8):1024-31. doi: 10.1111/aas.12156. Epub 2013 Jul 12.

Abstract

Background: Sevoflurane post-conditioning (SpostC) protects young hearts against ischemia-reperfusion injury. It is unknown whether the infarct-limiting effect is also maintained in aged cohorts and whether there are age-associated differences in the underlying mechanisms.

Methods: Young or old rats were randomly subjected to 30-min myocardial ischemia, followed by 120-min reperfusion in vivo, with or without SpostC in the presence or absence of phosphatidylinositol 3-kinase (PI3K) or mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor. Western blotting was used to determine the phosphorylation of protein kinase B (Akt) and extracellular signal-regulated kinase 1/2 (ERK1/2). Myocardial nicotinamide adenine dinucleotide (NAD(+) ) level was measured to indicate mitochondrial permeability transition pore (mPTP) opening.

Results: SpostC significantly decreased infarct size in young (35 ± 4% vs. 56 ± 3%, P < 0.05) but not old rats (45 ± 3% vs. 47 ± 4%, P > 0.05) compared with each control group. SpostC substantially augmented phosphorylation of Akt (0.74 ± 0.03 arbitrary units vs. 0.27 ± 0.03 arbitrary units, P < 0.05) or ERK1/2 (0.85 ± 0.04 arbitrary units vs. 0.29 ± 0.04 arbitrary units, P < 0.05) compared with control group, which was abolished by PI3K or MEK1/2 inhibitor in young rats, respectively, but failed to activate Akt and ERK1/2 in old rats. NAD(+) level (nmol/g tissue) was higher in SpostC group in young (118.57 ± 9.27 vs. 46.78 ± 4.54, P < 0.05) but not old rats (58.50 ± 7.16 vs. 61.15 ± 5.50, P > 0.05) compared with each control group. PI3K or MEK1/2 inhibitor abrogated the infarct-sparing effect and inhibition of loss of NAD(+) induced by SpostC in young rats, respectively.

Conclusion: SpostC-mediated cardioprotection in young rats is not effective in senescent rats, which may at least be the consequence of failure to activate Akt and ERK1/2, and resultant failure to inhibit mPTP opening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / physiology
  • Anesthetics, Inhalation / pharmacology*
  • Animals
  • Blotting, Western
  • Enzyme Activation
  • Ischemic Postconditioning / methods*
  • MAP Kinase Signaling System / drug effects
  • Methyl Ethers / pharmacology*
  • Mitochondria / drug effects
  • Mitogen-Activated Protein Kinases / metabolism
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / metabolism
  • NAD / metabolism
  • Permeability
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Sevoflurane
  • Ventricular Function, Left / drug effects

Substances

  • Anesthetics, Inhalation
  • Methyl Ethers
  • NAD
  • Sevoflurane
  • Proto-Oncogene Proteins c-akt
  • Mitogen-Activated Protein Kinases